Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 2Phase 2/3 1Phase 1/2 1

Status

Active not recruiting 2Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Cisplatin 20Docetaxel 19Capecitabine 19Oxaliplatin 14Drug Therapy 14Cyclophosphamide 14Paclitaxel 13Fluorouracil 12Radiotherapy 11apatinib 9Gemcitabine 9Doxorubicin 9Decitabine 9Methotrexate 8Epirubicin 8Carboplatin 8sintilimab 6Etoposide 6camrelizumab 5anlotinib 5XELOX 5Sorafenib 5Radiation 5Pemetrexed 5Neoadjuvant Therapy 5Leucovorin 5Idarubicin 5Dexamethasone 5Cytarabine 5Busulfan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Unknown × enzalutamide × Clear all
NCT05627752 2024-02-28

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Zhongnan Hospital

Phase 2/3 Unknown
120 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡